131 related articles for article (PubMed ID: 37778426)
1. Clinical and Dosimetric Results of Proton or Photon Radiation Therapy for Large (>5 cm) Hepatocellular Carcinoma: A Retrospective Analysis.
Hsieh RC; Lee CH; Huang HC; Wu SW; Chou CY; Hung SP; Lee CW; Krishnan S; Venkatesulu BP; Lee JC; Chou YC; Chan KM; Lin PT; Lee WC; Lin CC; Lin SY; Hong JH
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):712-724. PubMed ID: 37778426
[TBL] [Abstract][Full Text] [Related]
2. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival.
Sanford NN; Pursley J; Noe B; Yeap BY; Goyal L; Clark JW; Allen JN; Blaszkowsky LS; Ryan DP; Ferrone CR; Tanabe KK; Qadan M; Crane CH; Koay EJ; Eyler C; DeLaney TF; Zhu AX; Wo JY; Grassberger C; Hong TS
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):64-72. PubMed ID: 30684667
[TBL] [Abstract][Full Text] [Related]
3. The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation.
Cozzi L; Comito T; Loi M; Fogliata A; Franzese C; Franceschini D; Clerici E; Reggiori G; Tomatis S; Scorsetti M
Technol Cancer Res Treat; 2020; 19():1533033820980412. PubMed ID: 33287650
[TBL] [Abstract][Full Text] [Related]
4. Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis.
Cheng JY; Liu CM; Wang YM; Hsu HC; Huang EY; Huang TT; Lee CH; Hung SP; Huang BS
Radiat Oncol; 2020 Jun; 15(1):159. PubMed ID: 32605627
[TBL] [Abstract][Full Text] [Related]
5. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
[TBL] [Abstract][Full Text] [Related]
6. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
[TBL] [Abstract][Full Text] [Related]
7. Initial Report of a Prospective Dosimetric and Clinical Feasibility Trial Demonstrates the Potential of Protons to Increase the Therapeutic Ratio in Breast Cancer Compared With Photons.
Bradley JA; Dagan R; Ho MW; Rutenberg M; Morris CG; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):411-421. PubMed ID: 26611875
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric comparison between carbon, proton and photon radiation for renal retroperitoneal soft tissue sarcoma recurrence or metastasis after radical nephrectomy.
Ming X; Wang W; Shahnazi K; Sun J; Zhang Q; Li P; Hong Z; Sheng Y
Int J Radiat Biol; 2022; 98(2):183-190. PubMed ID: 34802361
[TBL] [Abstract][Full Text] [Related]
9. Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study.
Su TS; Liu QH; Zhu XF; Liang P; Liang SX; Lai L; Zhou Y; Huang Y; Cheng T; Li LQ
Radiat Oncol; 2021 Apr; 16(1):79. PubMed ID: 33882972
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Proton Beam Therapy in the Management of Thymoma: A Dosimetric Comparison and Acute Toxicities.
Parikh RR; Rhome R; Hug E; Tsai H; Cahlon O; Chon B; Goenka A
Clin Lung Cancer; 2016 Sep; 17(5):362-366. PubMed ID: 27372386
[TBL] [Abstract][Full Text] [Related]
11. Chest wall toxicity after hypofractionated proton beam therapy for liver malignancies.
Yeung R; Bowen SR; Chapman TR; MacLennan GT; Apisarnthanarax S
Pract Radiat Oncol; 2018; 8(4):287-293. PubMed ID: 29452863
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Ishikawa Y; Azami Y; Kato T; Tsukiyama I; Kikuchi Y; Hareyama M; Murakami M; Fuwa N; Hata M; Inoue T
Radiat Oncol; 2014 Jan; 9():26. PubMed ID: 24422711
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study.
Welsh J; Gomez D; Palmer MB; Riley BA; Mayankkumar AV; Komaki R; Dong L; Zhu XR; Likhacheva A; Liao Z; Hofstetter WL; Ajani JA; Cox JD
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1336-42. PubMed ID: 21470796
[TBL] [Abstract][Full Text] [Related]
14. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group.
Parzen JS; Hartsell W; Chang J; Apisarnthanarax S; Molitoris J; Durci M; Tsai H; Urbanic J; Ashman J; Vargas C; Stevens C; Kabolizadeh P
Radiat Oncol; 2020 Nov; 15(1):255. PubMed ID: 33148296
[TBL] [Abstract][Full Text] [Related]
16. What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy.
Toramatsu C; Katoh N; Shimizu S; Nihongi H; Matsuura T; Takao S; Miyamoto N; Suzuki R; Sutherland K; Kinoshita R; Onimaru R; Ishikawa M; Umegaki K; Shirato H
Radiat Oncol; 2013 Mar; 8():48. PubMed ID: 23497543
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety in Proton Therapy and Photon Therapy for Patients With Esophageal Cancer: A Meta-Analysis.
Zhou P; Du Y; Zhang Y; Zhu M; Li T; Tian W; Wu T; Xiao Z
JAMA Netw Open; 2023 Aug; 6(8):e2328136. PubMed ID: 37581887
[TBL] [Abstract][Full Text] [Related]
18. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.
Chadha AS; Gunther JR; Hsieh CE; Aliru M; Mahadevan LS; Venkatesulu BP; Crane CH; Das P; Herman JM; Koay EJ; Taniguchi C; Holliday EB; Minsky BD; Suh Y; Park P; Sawakuchi G; Beddar S; Odisio BC; Gupta S; Loyer E; Kaur H; Raghav K; Javle MM; Kaseb AO; Krishnan S
Radiother Oncol; 2019 Apr; 133():54-61. PubMed ID: 30935582
[TBL] [Abstract][Full Text] [Related]
19. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
[TBL] [Abstract][Full Text] [Related]
20. Sequential proton boost after standard chemoradiation for high-grade glioma.
Adeberg S; Bernhardt D; Harrabi SB; Uhl M; Paul A; Bougatf N; Verma V; Unterberg A; Wick W; Haberer T; Combs SE; Herfarth K; Debus J; Rieken S
Radiother Oncol; 2017 Nov; 125(2):266-272. PubMed ID: 29050959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
